Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target
Score
Regeneron Pharmaceuticals, Inc. price target
| REGN | |
|---|---|
| Low | $756.00 |
| Average | $887.79 |
| High | $1,100.00 |
| Upside vs current price | -6.9% |
The average target of $887.79 is -6.9% versus the current REGN price of $953.94.
Regeneron Pharmaceuticals, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 4 |
| Buy | 15 |
| Hold | 9 |
| Sell | 0 |
| Strong sell | 1 |
| Consensus | Buy |
29 analysts cover REGN.
Regeneron Pharmaceuticals, Inc. EPS and revenue estimates
REGN shows the next fiscal years with at least three analysts: 2026 EPS $67.55, 2027 EPS $70.32. A thinner year is left off this table.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $67.55 | $18.75B |
| 2027 | $70.32 | $20.10B |
Is Regeneron Pharmaceuticals, Inc. a buy or sell?
Of the 29 analysts covering Regeneron Pharmaceuticals, Inc., 19 rate it a buy (4 strong buy and 15 buy), 9 rate it a hold, and 1 rates it a sell (0 sell and 1 strong sell).
The REGN consensus label is Buy, beside 19 buy-side ratings and 1 sell-side ratings.
The average target of $887.79 implies -6.9% versus the current price of $953.94.
Those 29 ratings on REGN are a headcount, and the label on file is Buy.
Reading the Regeneron Pharmaceuticals, Inc. forecast
The REGN target band runs from $756.00 to $1,100.00. The average inside that band is $887.79.
Set next to the $953.94 REGN quote, that average is -6.9%.
Ratings on the Regeneron Pharmaceuticals, Inc. cluster: 19 of 29 analysts are on the buy side, 9 are at hold, and 1 is on the sell side, and the published consensus is Buy.
Over the last few months REGN drew 2 upgrades and 0 downgrades.
The REGN average target is little changed, $912.09 over the last month and $896.06 over the last quarter.
29 analysts publish on REGN, so one note does not swing the average by itself.
Regeneron Pharmaceuticals, Inc. forecast questions
What is the REGN price target?
The published range for REGN is $756.00 to $1,100.00, with an average of $887.79. That average is -6.9% versus the current price of $953.94.
Is Regeneron Pharmaceuticals, Inc. a buy or sell?
Of the 29 analysts covering Regeneron Pharmaceuticals, Inc., 19 rate it a buy, 9 rate it a hold, and 1 rates it a sell. The consensus is Buy, and the REGN headcount is 19 buy, 9 hold, and 1 sell.
What is the EPS estimate for Regeneron Pharmaceuticals, Inc.?
Analyst EPS estimates for Regeneron Pharmaceuticals, Inc.: 2026 $67.55, 2027 $70.32.
What is the revenue estimate for Regeneron Pharmaceuticals, Inc.?
Analyst revenue estimates for Regeneron Pharmaceuticals, Inc.: 2026 $18.75B, 2027 $20.10B.
How many analysts cover REGN?
29 analysts cover REGN. Their consensus on REGN is Buy, across those 29.